The gadgets that enable blind people to see
EyeMusic is an app and mini camera system that conveys colors, shapes and location of objects by converting images into “soundscapes” for the brain to interpret visually. Blind individuals can be trained to recognize the letters of the alphabet, “see” pictures of animals, and even find an object or person in a complex visual landscape. A version of the app is available free on the Apple App Store and Google Play.
Commercializing and eventually combining EyeCane and EyeMusic could give unprecedented self-navigation capabilities to blind people, says Daphna Rosenbaum, CEO of RenewSenses, a pre-startup based on Amedi’s research in the medical neurobiology department of the university’s Institute for Medical Research Israel-Canada. “The white cane is from 1921,” Rosenbaum tells ISRAEL21c. “The 21st century high-tech world hasn’t effectively answered the mobility needs of blind people.”
Amir and his team have exhibited the EyeCane prototype at global conferences and exhibitions, and testers in Israel have given enthusiastic testimonials, she says. “What we offer is independence in understanding and interpreting one’s surroundings using the natural brain processing of interpreting the landscape and objects,” says Rosenbaum. “No machine is as sophisticated as the brain and our solution is based on its elasticity and sensory substitution abilities.” Amedi received a European Research Council grant to develop the SSDs, whose patents are owned by Yissum, the technology transfer arm of the Hebrew University. Yissum has spun out 110 companies including superstars such as Mobileye, BriefCam, OrCam and Betalin Therapeutics.
Challenging conventional notions
Yaacov Michlin, CEO of Yissum, says the Amedi lab’s “amazing” research challenges the conventional notion that the brain is divided into distinct sensory regions. “They demonstrate that people have the ability to take information from one sense and present it in another, thus enabling blind people to ‘see’ by using other senses such as touching or hearing,” he said.
With the encouragement of Yissum, RenewSenses entered Brainnovations in May to build a business model and get the products to people who are waiting for them, Rosenbaum says. The initial version of EyeCane could be available within three or four months of raising production funds. “The Brainnovations accelerator helps us understand the medical ecosystem, including reimbursement and regulation, and governmental programs like the Innovation Authority [of the Ministry of Economy and Industry],” she says. “It also gives us access to mentors and impact investors, philanthropies, angel investors and VCs as we finalize our business plan.”
Rosenbaum says that EyeCane and EyeMusic are based on different scientific insights than are potentially similar technologies under development elsewhere. Using infrared rather than ultrasonic rays gives EyeCane has superior accuracy, and it is expected to be more affordable than competitive devices. EyeMusic is the only system of its kind that can effectively convey color and brightness information. “We plan to combine the two products and when we do, we will have no competitors,” she says.
“We’ll have a mobility aid with the option of understanding color, and other features like a compass and eventually image processing or object recognition. If a person detects an object he can zoom in, take a picture and EyeMusic will show him what it is. Instead of just being told there’s a chair, it’s like opening your eyes and seeing it.”
RenewSenses currently has a fulltime R&D manager and Rosenbaum hopes to add a production manager and sales/marketing manager when it gets funded. All of the current eight Brainnovations startups will present at a pitch day on September 18 at Google Tel Aviv, where the accelerator is housed. The other seven are BioEye (developing an ADHD diagnostic device using the front camera of mobile phones), Pauzzitive Life (developing a mobile application for treating lifestyle addictions), TailorMed (using machine learning to improve quality and speed of medical image diagnostics), InnoSphere (developing a brain-stimulating device to treat ADHD), MyDopa (using machine learning to adjust the medication dosage of Parkinson patients), Sentidio (developing software to improve the social skills of autistic children) and Re:Mind (developing an at-home diagnostic helmet to detect an early-stage stroke).
For more information, click here.
Abigail Klein Leichman